458 Studies Now Enrolling
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
A Study to Test a New Drug (PXT3003-06) in Patients with Charcot-Marie-Tooth Type 1A (CMT1A)
| Sponsor: | Pharnext |
| Enrolling: | Male and Female Patients |
| Study Length: | 15 Months |
| Clinic Visits: | 8 |
| IRB Number: | AAAT5360 |
| Contact: | Raisy Fayerman: 212-305-6035 / rf2632@cumc.columbia.edu |
Additional Study Information:
The main purpose of this study is to investigate how effective PXT3003 is when compared to a placebo, on the disease progression and symptoms of CMT1A. The study also aims to assess the safety and tolerability (whether side effects of a medication can be handled by patients) of PXT3003. We are enrolling male and non-pregnant female subjects, aged 16 to 65 years with a genetically proven diagnosis of CMT1A.
This study is closed
Do You Qualify?
| Are you a male or non-pregnant female, aged 16 to 65 years? | Yes | No |
| Have you received a genetically-proven diagnosis of CMT1A? | Yes | No |
| Have you been on a stable dose of prescribed psychoactive drugs in the past 4 weeks? | Yes | No |
| Have you been on a stable dose of prescribed or 'over-the-counter' (OTC) analgesic medications in the past 2 weeks? | Yes | No |